Active management may be under attack, but don’t tell that to Barron’s. Every year the venerable paper hosts an investor roundtable featuring some of the industry’s leading voices and largest active asset managers. The day long event offers a chance to hear their thoughts on a wide variety of topics including the economy and pressing global issues. Readers… Read More »
It was just one year ago when Biogen(BIIB) spun off hemophilia and blood disorder specialist Bioverativ(BIVV). With the stock trading in the 40s post-spin, we highlighted some disparate analyst opinions of the spin. The most bullish, Gabelli & Company, has a price target of $58 for Bioverativ stock. This past Friday, Bioverativ stock closed at $64.11, above Gabelli’s… Read More »
Just months after being spun off from Baxter International(BAX), Baxalta found itself the target of an intense pursuit by Shire Pharmaceuticals(SHPG). Baxalta resisted, but, ultimately agreed to a deal which closed earlier this year. Barron’s sees good things ahead for the combined company. In an article this weekend, the venerable publication points out that merely by achieving a… Read More »
AbbVie(ABBV) surged out of the gate following its January 2013 spinoff from Abbott Laboratories(ABT). By December 2014, the stock price had doubled. Since then, however, the stock languished, continuing to trade below its December 2014 highs. Despite efforts to diversify, Humira, which is now off patent, accounts for 60% of revenue. Barron’s reports that Raymond James now thinks… Read More »
Abbott Labs(ABT), which spun off AbbVie(ABBV) in one of the largest spinoffs in recent years, is preparing to make a $25 billion bid for St. Jude Medical(STJ) according to a report in the Financial Times. Abbott and St Jude, which is based in St Paul, Minnesota, already have a strong alliance in the field of cardiovascular devices, and… Read More »
Yesterday morning we noted Shire’s (SHPG) unsolicited all-stock offer for recent Baxter (BAX) spinoff Baxalta (BXLT). The proposal offered to exchange any Baxalta shares for 0.1687 Shire ADRs, implying a value of $45.23 per Baxalta share. Of course, Shire promptly slumped over 5% so the effective price went down somewhat. The company responded later in the afternoon with a press release… Read More »
Amidst this great Summer Of Spin, what are the best prospects? According to Forbes’ Antoine Gara, who has also noted the flurry of spinoffs: PayPal and Baxalta(BXLT). About PayPal: PayPal is a leader in online payments, with high margins and strong revenue growth. It could prove valuable to tech giants like Google, Apple, Microsoftand Facebook, who are all toying… Read More »
13F season is always fun as it provides a rare (albeit delayed) glimpse into the thinking of large money managers and hedge funds. Of course, due to the significant time lag (~45 days), the exclusion of certain securities (shorts, derivatives etc.) and varying investment strategies and holding periods, the usefulness of such data is…questionable in many cases. Not… Read More »
Amidst our exhaustive coverage of the Abbott (ABT)/AbbVie (ABBV) separation, there has been no consensus as to which company is the ‘better’ one to own. Some people like AbbVie’s higher dividend yield while others prefer Abbott’s growth prospects. Ahhh what is an uninformed investor to do? Luckily, the self-appointed people’s champion stockpicker, CNBC’s Jim Cramer, has weighed in… Read More »
Set a million monkeys loose with Yahoo Finance and a word processor, and what do you get? The answer, it would appear, is Seeking Alpha, a content farm with no particular editorial standards. We wrote last week about blatant, significant errors being covered up without acknowledgement. This morning, we encountered another wastebasket-worthy piece on AbbVie(ABBV). Imagine writing about… Read More »
AbbVie(ABBV) is a behemoth of a company following its spinoff from Abbott Laboratories(ABT), but it is a one-legged giant. The chorus of concern around the companies prospects has centered on its extreme dependence on a single drug, Humira, which accounts for 50% of revenues and 70% of profits. There has been speculation that the firm would use its… Read More »
This has been a month where spinoff news has been dominated by a massive deal, the spin off of AbbVie(ABBV) by Abbott Laboratories(ABT). Yet, the vast majority of spinoffs involve tiny companies. We’ve written about some of the most ridiculous. Today, we have an announcement from one, that, while slightly larger, is still a microcap. Oculus Innovative Sciences(OCLS)… Read More »
We wrote yesterday about a flawed article on SeekingAlpha about AbbVie(ABBV) and Abbott Laboratories(ABT) which contained information which was extremely erroneous(off by over $15 billion), and built a thesis based on that false data. The article, which can be found here, has been edited extensively, but something is missing: there is no indication anywhere on the page that… Read More »
AbbVie(ABBV) is one of the most massive spinoffs we’ve seen, so every piece of news or analysis is of interest to us. Hence it was with great interest that we noted that Seeking Alpha published “AbbVie’s Shares Are More Appealing Than Abbott’s Following The Spin-Off” this morning. We were pleased to see author Robert Broens put a stake… Read More »
Not wasting any time, AbbVie(ABBV) declared a $.40 quarterly dividend on Friday, two days after its spin off from Abbott Laboratories(ABT). At Friday’s closing price of $34.39, the stock yields 4.65%. The dividend will be paid on February 15, 2013 to shareholders as of the close of business on January 15, 2013. For former Abbott shareholders continuing to… Read More »